My research focuses on understanding the genetic and molecular mechanisms that underlie the initiation and progression of B-cell non-Hodgkin's lymphomas in order to define clinically-relevant biomarkers.
Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma. Leukemia (2018) 32(5):1258-1263. PMID: 29568095
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Nat Cell Biol (2017) 19(9):1093-1104. PMID: 28825697
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nature Genetics (2016) 48(2):183-8. PMID: 26691987
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nature Genetics (2014) 46(2):176-81. PMID: 24362818
I have a research interest in B-cell Non-Hodgkin’s lymphoma. Our current focus is on follicular lymphoma, an indolent malignancy that remains incurable and for which the typical clinical course is one where patients relapse on several occasions eventually becoming therapy resistant. Our main research questions are to:
To address these questions, we aim to utilise primary lymphoma samples in combination with cutting-edge tools, in vitro and in vivo approaches.
Correction: Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Araf S, Wang J, Korfi K et al. Leukemia (2019) 33(2) 1540
Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant. Araf S, Wang J, Ashton-Key M et al. Haematologica (2019) 104(2) e174-e177
Rituximab as a first step in tackling transformation. Okosun J, Kridel R, Fitzgibbon J Lancet Haematol (2018) 5(2) e326-e327
Precision medicine and lymphoma. Heward JA, Kumar EA, Korfi K et al. Curr Opin Hematol (2018) 25(2) 329-334
Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma. Araf S, Wang J, Korfi K et al. Leukemia (2018) 32(2) 1261-1265
Predicting early relapse in follicular lymphoma: have we turned a corner? Araf S, Okosun J, Fitzgibbon J Lancet Oncol (2018) 19(2) 441-442
Early loss of Crebbp confers malignant stem cell properties on lymphoid progenitors. Horton SJ, Giotopoulos G, Yun H et al. Nat Cell Biol (2017) 19(2) 1093-1104
Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Mansouri L, Noerenberg D, Young E et al. Blood (2016) 128(1) 2666-2670
TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses Kotsiou E, Okosun J, Besley C et al. Blood (2016) 128(1) 72-81
The routes for transformation of follicular lymphoma Okosun J, Montoto S, Fitzgibbon J Current Opinion in Hematology 23(1) 1-1For additional publications, please click here
Dr Giuseppe Palladino
Clinical Research Fellows/PhD students
Dr Emil Kumar (co-supervision with Professor Jude Fitzgibbon), Dr Lucy Pickard
Academic Clinical Fellows
Dr Edward Poynton
I graduated in medicine from the University of Cambridge and subsequently undertook my medical and specialty registrar haematology training in London. My research interests in lymphoma biology was developed during my Kay Kendall funded Clinical Research Fellowship with Professor Jude Fitzgibbon at the Barts Cancer Institute where I investigated the genetic heterogeneity and tumour evolution underlying follicular lymphoma and its progression. I was awarded the Royal College of Pathologists Specialty Research Medal for this work.
I returned to the Barts Cancer Institute as a Clinical Senior Lecturer in 2017 and will also be working with collaborators at the Francis Crick Institute.
2017 to present: Clinical Senior Lecturer
2011-2015: Kay Kendall Clinical Research Fellow, Barts Cancer Institute
2015: PhD, Queen Mary University of London
2011: FRCPath, Royal College of Pathologists
2008: MRCP, Royal College of Physicians
2004: MB BChir, University of Cambridge
2002: BA (Hons) Natural Sciences, University of Cambridge